Related Experiment Videos
Ventricular enlargement and reduced survival after myocardial infarction
Insights
Captopril treatment reduced ventricular volume and improved survival in rats after myocardial infarction. This suggests potential for similar benefits in human heart disease patients, warranting clinical trials.
Area of Science:
- Cardiology
- Pharmacology
- Experimental Medicine
Background:
- Increased ventricular volume is a key predictor of poor survival in heart disease.
- Ventricular dilatation progresses significantly after myocardial infarction, impacting long-term prognosis.
Purpose of the Study:
- To investigate the remodeling of the infarcted left ventricle in rats.
- To test the hypothesis that captopril can attenuate ventricular dilatation by reducing wall stress.
- To evaluate the impact of captopril on survival rates post-myocardial infarction.
Main Methods:
- Induction of myocardial infarction in a rat model.
- Administration of captopril to assess its effect on ventricular volume and cardiac output.
- Long-term monitoring of survival rates in treated and control groups.
Main Results:
- Captopril-treated rats exhibited smaller ventricular volumes at comparable pressures.
- Cardiac output was maintained or improved in captopril-treated rats.
- Long-term captopril therapy significantly prolonged survival in rats with experimental myocardial infarction.
Conclusions:
- Progressive ventricular enlargement after myocardial infarction can be attenuated by captopril.
- Captopril therapy holds potential for improving survival in patients recovering from myocardial infarction.
- Clinical trials are necessary to confirm these findings in human patients.
Abstract:
Increased ventricular volume is one of the most powerful predictors of reduced survival in patients with heart disease. Despite its well-documented prognostic significance, the magnitude of the progression of ventricular dilatation from the acute to the chronic phase of myocardial infarction has only recently been appreciated. In an experimental preparation of myocardial infarction in rats, left ventricular cavitary volume increased progressively even after histologic resolution of the infarct region. We hypothesized that this remodeling of the infarcted left ventricle was a response to an increase in both systolic and diastolic wall stresses and that captopril, by reducing wall stress, would attenuate the process. For comparably sized infarcts, the captopril-treated rats had smaller ventricular volumes at common distending pressures, yet they had maintained or improved cardiac output. Most importantly, long-term captopril therapy also prolonged the survival of these rats with experimental myocardial infarction. The implication of these animal studies is that the potential exists for the attenuation of progressive ventricular enlargement and improvement of survival of patients recovering from a myocardial infarction. At the present time, no information is available in patients as to the therapeutic potential of interrupting this insidious process of ventricular dilatation in order to improve survival. Clinical trials are required to determine whether salutary benefits similar to those observed in animals can be provided to patients recovering from a myocardial infarction.